Objective: To evaluate the effects of a new antifungal agent, S1123, on controlling fungal infection on burn wound in vitro and in clinic. Methods: Compare their antifungal effects with 3 different antifungal drugs, naftifine, ketoconole and S1123 by testing their minimal inhibitory concentration (MIC). S1123 and a control drug were used to treat burn wound. The crusts were taken to culture before and after treatment for calculating the negative rate. One thousand nine hundred and twenty-seven patients suffered superficial mycoses on naval vessels were treated with S1123 cream. Results: S1123 was active in vitro against a broad spectrum of fungal and yeast pathogens. MIC of Aspergillus and Candida, 2 main pathogenic genura, was 0.156，0.625 μg/ml. In the clinical administration, invasive fungi of 79.71%burn wound disappeared in 3 d. Compared with the controls, the difference being signifficant statistically (P<0.01). The effective rate on superficial mycoses was 95.6%. Conclusion: S1123 is an new effective external antifungal drug.